MOTS-c 10mg dosage calculator: how the math actually works

Last updated 2026-07-24

What does a MOTS-c 10mg dosage calculator actually calculate?

It converts one vial's total peptide mass into a volume you can draw up in a syringe. That's it. A MOTS-c 10mg dosage calculator takes three inputs (total peptide in the vial, in this case 10mg, the volume of bacteriostatic water you add, and your target dose in mg or mcg) and spits out how many units to pull on a standard U-100 insulin syringe. It is not calculating a clinically validated human dose. Nobody has published a dose-ranging human trial for MOTS-c that would let a calculator say "this mcg amount produces this metabolic effect in people." What exists is animal pharmacology, mostly mice, using doses expressed as mg per kg of body weight ^[1]. A calculator that outputs a mcg number for a 70 kg adult is doing arithmetic, not clinical translation. Keep that distinction in your head through the rest of this. The practical value of a reconstitution calculator is real: it prevents math errors that lead to a 10x under- or overdose from a decimal slip. The practical value of a "how much MOTS-c should I take" calculator is much thinner, because the underlying human dose-response curve doesn't exist yet in the literature.

How do I use a MOTS-c reconstitution calculator step by step?

A mots-c reconstitution calculator needs exactly three numbers: total peptide mass in the vial (mg), diluent volume added (mL), and your intended per-dose amount (mg or mcg). From those it back-calculates syringe units. Step 1: Confirm vial content. This article assumes a 10mg vial, so total peptide mass = 10,000 mcg. Step 2: Pick a diluent volume. Bacteriostatic water is standard for multi-use vials because the benzyl alcohol preservative limits bacterial growth across repeated draws; sterile water without a preservative is for single-use only. Common choices are 1mL, 2mL, or 3mL. Step 3: Calculate concentration. Concentration (mcg/mL) = total mcg ÷ mL of diluent. For a 10mg (10,000 mcg) vial:

Step 4: Convert your target dose to units. A U-100 insulin syringe measures in units where 100 units = 1 mL. Units needed = (target dose in mcg ÷ concentration in mcg/mL) x 100. Example: if you reconstitute a 10mg vial with 2mL (5,000 mcg/mL) and the target is 500 mcg, you'd draw 10 units. If you reconstitute with 5mL (2,000 mcg/mL) for the same 500 mcg target, you'd draw 25 units. Same dose, different volume, because the concentration changed. This is the entire mechanism of a mots c reconstitution calculator: it's unit conversion, and getting the diluent volume input wrong is the single most common user error.

Is there an FDA-approved or clinically established human MOTS-c dose?

No. There is no FDA-approved MOTS-c product and no established human dosing regimen in peer-reviewed literature. Every dose figure circulating online is either extrapolated from animal studies, borrowed from unregulated compounding practice, or simply guessed. MOTS-c is not listed among FDA-approved drug products in the Drugs@FDA database ^[2]. It also does not appear on the FDA's 503A bulk drug substances list for human drug compounding ^[3], nor the 503B bulks list for outsourcing facilities ^[4]. The FDA's nomination list for substances under evaluation is the closest thing to an official regulatory conversation about compounded MOTS-c, and inclusion on a nomination list is not the same as approval or a green light for compounding ^[5]. What this means practically: a MOTS-c dosage calculator for weight loss that outputs "take 5mg twice weekly" is repeating a number that has propagated through forums and vendor sites, not a number derived from a published human pharmacokinetic study. The original mouse work that put MOTS-c on the map used doses like 15 mg/kg administered by intraperitoneal injection to demonstrate reduced diet-induced obesity and improved insulin sensitivity ^[6]. Scaling 15 mg/kg to a human isn't a simple ratio conversion either, because interspecies dose scaling depends on metabolic rate, body surface area, and pharmacokinetics that haven't been characterized for MOTS-c in humans at all.

Why do people search for a MOTS-c dosage calculator for weight loss specifically?

Because the foundational 2015 Cell Metabolism paper showed MOTS-c administration reduced diet-induced obesity and improved insulin resistance in mice, and that finding is the seed of almost every weight-loss claim about this peptide ^[6]. It's a real finding. It is also a mouse finding, using a specific injected dose in a specific diet-induced obesity model, not a demonstrated effect in humans at any dose. A 2023 Metabolites review describes MOTS-c as functionally preventing metabolic disorders, again synthesizing largely preclinical mechanistic work ^[7]. A 2022 Pharmacological Research paper found MOTS-c relieved hyperglycemia and insulin resistance specifically in a gestational diabetes model ^[8], and a 2025 paper in Experimental & Molecular Medicine reported MOTS-c prevents pancreatic islet cell senescence in models of diabetes progression ^[9]. These are legitimate, interesting mechanistic threads. None of them is a human weight-loss trial with a dose-response curve you could safely build a calculator around. If you're searching "mots c dosage calculator for weight loss" hoping for a number backed by a human RCT, that number doesn't exist yet. What exists is rodent metabolic pharmacology and a lot of downstream extrapolation. For a fuller breakdown of what the evidence actually supports versus what's marketing gloss, see mots-c.

What is MOTS-c and why does dosing even matter here?

MOTS-c is a 16-amino-acid peptide encoded within the mitochondrial genome, inside the 12S rRNA region, discovered through its metabolic effects rather than its origin story. It behaves less like a typical hormone and more like a stress-response signal the mitochondria send to the rest of the cell. A 2018 Cell Metabolism paper showed MOTS-c translocates to the nucleus under metabolic stress and directly regulates nuclear gene expression, including antioxidant response pathways, acting through what the researchers describe as a retrograde mitochondria-to-nucleus signaling mechanism ^[10]. A 2019 BioEssays review frames MOTS-c as a mitochondrial-encoded regulator of the nucleus, a genuinely unusual role for a peptide originating from mitochondrial DNA ^[11]. More recent mechanistic work has found MOTS-c binds and activates CK2 to modulate skeletal muscle function ^[12], a distinct pathway from its nuclear translocation role. Dosing matters because MOTS-c's effects across the published literature are consistently concentration- and context-dependent: different tissue effects show up at different doses in different disease models (cardiac, pulmonary, ovarian, bone, muscle), and none of that dose-response mapping has been done in humans. A calculator can tell you precisely how many mcg are in your syringe. It cannot tell you what mcg amount produces a specific effect in a person, because that data point hasn't been generated by controlled human research yet.

What does 'exercise mimetic' actually mean for MOTS-c, and is it accurate?

"Exercise in a pill" is a marketing shorthand, not a peer-reviewed conclusion. The real research shows MOTS-c levels change with exercise and that MOTS-c administration produces some exercise-adjacent effects in animal models, which is meaningfully different from claiming a peptide replicates what exercise does to a human body. A 2022 Diabetes & Metabolism Journal paper on mitohormesis specifically examines MOTS-c's relationship to exercise-induced mitochondrial stress adaptation ^[13], and a 2021 review in Biochimica et Biophysica Acta looked at mitochondrial-derived peptides and exercise broadly, not MOTS-c alone ^[14]. These papers describe a plausible biological relationship (exercise triggers mitochondrial stress responses that involve MOTS-c signaling), not a demonstrated equivalence between injecting the peptide and doing a workout. Separately, a 2021 paper found MOTS-c reduces myostatin and muscle atrophy signaling in animal models ^[15], and a 2024 paper reported MOTS-c attenuates immobilization-induced skeletal muscle atrophy by suppressing lipid infiltration ^[16], again in animal models. A 2022 Peptides paper found MOTS-c promotes muscle differentiation in vitro, meaning in cultured cells, not in living muscle tissue ^[17]. Interesting mechanistic biology. Not a substitute for exercise, and no human trial has tested that substitution claim directly.

What other effects has MOTS-c shown, and at what evidence level?

The published MOTS-c literature spans several organ systems, and almost all of it sits at the cell-culture or rodent-model stage. Here's an honest inventory, organized by evidence tier. Metabolic and diabetes-related: reduces obesity and insulin resistance in diet-induced obese mice ^[6]; relieves hyperglycemia in a gestational diabetes mellitus model ^[8]; prevents pancreatic islet cell senescence in a diabetes model ^[9]; reviewed as a candidate against aging-related metabolic disease in a 2023 Diabetes & Metabolism Journal paper ^[18]. Cardiovascular and pulmonary: described as a candidate mechanism in diabetic cardiomyopathy in a 2025 review, itself titled with a question mark reflecting how preliminary the claim is ^[19]; shown to attenuate lung ischemia-reperfusion injury via a MYH9-dependent pathway in a 2025 Redox Biology paper ; promotes glycolysis via AMPK-HIF-1α-PFKFB3 signaling to reduce cardiopulmonary bypass-induced lung injury in a 2025 paper ; suppresses ferroptosis in acute lung injury following myocardial ischemia reperfusion via PPARγ signaling . Musculoskeletal: reviewed for a role in bone metabolism regulation ; shown to attenuate cartilage degradation in an osteoarthritis model via an Nrf2-dependent mechanism ; used in a hydrogel formulation to enhance stem cell activity for intervertebral disc degeneration in a 2025 materials science paper . Other systems: shown to suppress ovarian cancer progression in a 2024 Advanced Science paper by attenuating a specific deubiquitination pathway ; found to have an antiviral role during hepatitis B infection via mitochondrial remodeling in a 2024 Gut paper ; shown to participate in plasma membrane repair by facilitating TRIM72 translocation ; investigated for anti-pulmonary fibrosis activity and for reducing airway barrier dysfunction in allergic asthma ; found to improve survival of soft tissue transplantation via lysosomal membrane effects in a 2026 Autophagy paper ; shown to combat diabetic liver fibrosis by targeting Keap1-Nrf2-Smad2/3 signaling, explicitly framed by the authors as mimicking exercise at the molecular pathway level in that specific model . That's a genuinely long list, and it's exactly why researchers are excited about this peptide. Every single one of those findings is preclinical: cell culture, mouse, or rat. None is a completed human clinical trial. A 2023 Frontiers in Endocrinology review calls MOTS-c "a promising mitochondrial-derived peptide for therapeutic exploitation" ^[1], which is an accurate summary: promising, and not yet exploited in validated human protocols. One 2018 Rejuvenation Research paper adds a note of caution, reporting that mitochondrial-derived peptides as a class can under some conditions exacerbate cellular senescence markers , a reminder that this biology isn't uniformly protective in every context tested.

How does the injectable peptide space (including MOTS-c) get regulated right now?

Compounding pharmacies operate under 21 U.S.C. 353a, which lets a licensed pharmacist compound a drug for an identified patient based on a valid prescription, but that authority is built around FDA-approved drugs and substances on specific bulk lists, not an open license to compound anything . The FDA maintains two relevant lists: the 503A bulks list under 21 CFR 216.23 for traditional compounding pharmacies , and the 503B bulks list under 21 CFR 216.24 for larger outsourcing facilities ^[4]. MOTS-c does not appear on either as an approved bulk substance as of this writing. There is a separate nomination process where substances are proposed for evaluation and possible addition to these lists, and MOTS-c has appeared in that nomination pipeline, but nomination is not approval ^[5]. Separately, 21 CFR 201.128 defines "intended use" for drug labeling purposes, which matters here because how a product is marketed (a treatment claim versus a "research use only" label) determines which regulatory bucket it falls into and what enforcement exposure a seller has . A lot of MOTS-c sold online is labeled research use only precisely to sidestep this framework, which tells you something about where the regulatory ground actually stands, not where marketing copy claims it stands. A 2026 Sports Medicine paper reviewing the safety and efficacy of approved and unapproved peptide therapies for athletic performance is a useful read here, because it treats MOTS-c as one of several unapproved compounds circulating in that market with a genuinely thin safety data set in humans .

What are the real risks of guessing at a MOTS-c dose?

The biggest practical risk isn't exotic toxicity, it's math error compounded by product inconsistency. Reconstitution mistakes (wrong diluent volume, misread vial concentration, unit conversion slips between mg and mcg) are the most common way people end up with a dose 5x or 10x off from what they intended. Beyond math, there's a sourcing problem: unregulated peptide vendors are not held to the same purity, sterility, and potency-verification standards as an FDA-approved drug listed in the Drugs@FDA database ^[2]. A vial labeled 10mg may not contain 10mg. Nobody publishes third-party assay data for most of these products, and there's no regulatory body checking. There's also a human-safety data gap that a calculator can't paper over. None of the studies cited in this article involved a completed human safety trial establishing an acceptable dose range, an adverse event profile, or a maximum tolerated dose in people. If you're set on using it, the more defensible path is working through a provider who reviews your case and sources through a pharmacy that actually tests what it ships, which is the model MOTS-c Co points readers toward: a provider-reviewed pathway with a named compounding pharmacy partner handling fulfillment, rather than an anonymous vial from an unverified website. For a broader risk rundown, see mots-c side effects.

MOTS-c 10mg vs other common vial sizes: how does the math change?

Vial size changes the concentration math but not the underlying uncertainty about what dose is appropriate. Here's how a 10mg vial compares to other sizes commonly sold, assuming the same 2mL reconstitution volume.

A 10mg vial reconstituted with 2mL is a common middle-ground choice because it produces a concentration (5,000 mcg/mL) that maps to reasonably precise syringe draws without needing sub-unit measurements on a standard U-100 syringe. Going with less diluent (say 1mL) doubles the concentration and halves the draw volume for the same dose, which can matter if you're trying to keep injection volume small, but it also makes small dosing errors proportionally larger since you're working with fewer units per draw. None of this changes the core caveat: whichever vial size and dilution you land on, the target mcg number itself is not derived from a validated human dose-response study. The calculator gets you an accurate draw for whatever number you input. It cannot validate that the number itself is correct for you. If you're weighing vial sizes and injection logistics, mots-c peptide injection covers technique, and mots c dosage covers the range of protocols circulating in practice today.

What should I actually do with a MOTS-c dosage calculator, practically?

Use it for the math, not for the medical decision. That's the honest summary. If you're going to use a MOTS-c 10mg dosage calculator, use it to double-check your reconstitution arithmetic (concentration, syringe units, injection volume) so you don't make a decimal-point mistake. Don't use it as a substitute for talking to a provider who can look at your bloodwork, your health history, and current literature and give you an actual clinical opinion. And don't treat any output number as validated just because a calculator produced it with confidence; a calculator will confidently compute nonsense if you feed it a made-up target dose. The most defensible path right now, given how thin the human data is, is a provider-reviewed protocol sourced through a pharmacy that does its own potency and sterility testing, rather than a random vial off a marketing website with no assay behind it. That's the structure MOTS-c Co recommends: provider review first, verified pharmacy fulfillment second, calculator math as a supporting tool, never as the decision-maker. If you want the fuller evidence picture before deciding anything, start with mots-c, and if timing questions are what's driving your search, when to take mots-c peptide covers what's known and unknown about timing relative to meals and training.

Frequently asked questions

How do I calculate MOTS-c dosage from a 10mg vial?

Divide the total peptide mass (10,000 mcg) by the mL of bacteriostatic water you add to get concentration in mcg/mL. Then divide your target dose by that concentration and multiply by 100 to get insulin syringe units. Example: 10mg in 2mL = 5,000 mcg/mL; a 500 mcg dose needs 10 units. This is unit conversion, not a validated clinical dosing recommendation.

Is there an official or FDA-approved MOTS-c dose for humans?

No. MOTS-c has no FDA-approved product listing in the Drugs@FDA database and does not appear on the 503A or 503B bulk drug substance lists that govern compounding. Any dose figure you see online comes from animal studies, informal practice, or extrapolation, not from a completed, published human dose-ranging trial.

What's a good starting point for a MOTS-c reconstitution calculator?

Most people reconstitute a 10mg vial with 1 to 5mL of bacteriostatic water, with 2mL being a common middle ground (5,000 mcg/mL, giving reasonably precise syringe draws on a standard U-100 syringe). The diluent volume you choose doesn't change total peptide amount, only the concentration and draw volume per dose.

Does MOTS-c actually help with weight loss in humans?

The core weight-loss evidence is a 2015 Cell Metabolism study showing MOTS-c reduced diet-induced obesity and insulin resistance in mice, not humans. Later papers extend this to gestational diabetes and islet cell senescence models, still in animals. No published human trial has demonstrated a weight-loss effect at any specific dose.

Is MOTS-c really 'exercise in a pill'?

That phrase is marketing shorthand, not a research conclusion. Studies link MOTS-c to exercise-induced mitochondrial stress signaling (mitohormesis) and show it reduces myostatin and muscle atrophy signaling in animal models, but no study has shown injecting MOTS-c replicates the systemic effects of a workout in humans.

What's the difference between bacteriostatic water and sterile water for reconstitution?

Bacteriostatic water contains a preservative (usually benzyl alcohol) that inhibits bacterial growth across multiple draws from the same vial, making it suitable for multi-dose use. Plain sterile water has no preservative and is intended for single-use reconstitution only, since it doesn't prevent contamination once the vial is punctured repeatedly.

Why do MOTS-c dosage calculators give different mcg recommendations?

Because there's no single validated human dose to standardize on. Different calculators and vendors are repeating different numbers pulled from animal mg/kg studies, informal community practice, or vendor marketing, none of which is backed by a published human pharmacokinetic or dose-response trial.

Can I convert mouse study doses directly to a human MOTS-c dose?

Not reliably. The foundational mouse study used doses around 15 mg/kg by intraperitoneal injection. Converting mg/kg animal doses to human equivalents normally requires body-surface-area scaling and pharmacokinetic data that hasn't been established for MOTS-c in people, so any human number derived this way is an estimate, not a validated dose.

How many units of MOTS-c should I draw from a 10mg vial for a 500 mcg dose?

It depends entirely on your reconstitution volume. At 2mL diluent (5,000 mcg/mL), a 500 mcg dose is 10 units on a U-100 insulin syringe. At 5mL diluent (2,000 mcg/mL), the same 500 mcg dose is 25 units. Always calculate from your actual concentration, not a generic chart.

Is MOTS-c legal to buy and use?

MOTS-c isn't on the FDA's 503A or 503B bulk drug substance lists, and it has no approved drug status, so it exists in a gray zone typically sold as 'research use only.' That labeling is a regulatory workaround, not a safety endorsement, and buying it for personal use puts you outside any FDA-reviewed quality or dosing framework.

What does the research actually show MOTS-c doing, beyond weight loss claims?

Several preclinical effects across organ systems: reduced lung injury in ischemia-reperfusion and cardiopulmonary bypass models, suppressed ovarian cancer progression, antiviral activity against hepatitis B, reduced cartilage degradation in osteoarthritis models, and roles in bone metabolism and muscle atrophy. All of this is cell-culture or animal-model evidence, not human trial data.

Should I trust a MOTS-c dosage calculator for weight loss found on a vendor website?

Use it only to check reconstitution math, not to validate the dose itself. Vendor-provided target doses aren't derived from published human trials. A calculator will accurately convert whatever number you enter into syringe units, but accurate arithmetic doesn't make the underlying dose recommendation medically validated.

Sources

1. Frontiers in Endocrinology, 2023 (PMID 36761202): Reviews MOTS-c as a promising mitochondrial-derived peptide for therapeutic exploitation, summarizing preclinical evidence.
2. Drugs@FDA database: MOTS-c has no listed FDA-approved drug product in the Drugs@FDA database.
3. FDA, bulk drug substances used in compounding under section 503A: Explains the 503A bulk drug substance framework governing what pharmacies may compound.
4. 21 CFR 216.24, the 503B Bulks List: Defines the 503B bulk drug substances list for outsourcing facilities, which MOTS-c does not appear on.
5. FDA, bulk drug substances nominated for use in compounding (current list): MOTS-c has appeared in the FDA nomination pipeline for bulk substance evaluation, distinct from approval.
6. Cell Metabolism, 2015 (PMID 25738459): MOTS-c administration reduced diet-induced obesity and improved insulin resistance in mice using doses around 15 mg/kg.
7. Metabolites, 2023 (PMID 36677050): Reviews MOTS-c's role in functionally preventing metabolic disorders, based on preclinical mechanistic work.
8. Pharmacological Research, 2022 (PMID 34798268): MOTS-c relieved hyperglycemia and insulin resistance in a gestational diabetes mellitus model.
9. Experimental & Molecular Medicine, 2025 (PMID 40855115): MOTS-c prevents pancreatic islet cell senescence to delay diabetes progression in model systems.
10. Cell Metabolism, 2018 (PMID 29983246): MOTS-c translocates to the nucleus and regulates nuclear gene expression in response to metabolic stress.
11. BioEssays, 2019 (PMID 31378979): Reviews MOTS-c's unusual role as a mitochondrial-encoded regulator of nuclear gene expression.
12. iScience, 2024 (PMID 39559755): MOTS-c modulates skeletal muscle function by directly binding and activating CK2.
13. Diabetes & Metabolism Journal, 2022 (PMID 35656563): Examines MOTS-c's relationship to exercise-induced mitohormesis and mitochondrial stress adaptation.
14. Biochimica et Biophysica Acta - General Subjects, 2021 (PMID 34520826): Reviews mitochondrial-derived peptides and their relationship to exercise physiology broadly.
15. American Journal of Physiology - Endocrinology and Metabolism, 2021 (PMID 33554779): MOTS-c reduces myostatin and muscle atrophy signaling in animal models.
16. 21 U.S.C. 353a, pharmacy compounding: Establishes the legal basis for pharmacy compounding for identified patients under a valid prescription.
17. 21 CFR 216.23, the final 503A Bulks List: Defines the 503A bulk drug substances list for traditional compounding pharmacies, which does not include MOTS-c.
18. 21 CFR 201.128, meaning of intended uses: Defines how product labeling and marketing claims determine a drug's intended use classification under FDA rules.
19. Sports Medicine, 2026 (PMID 41966639): Reviews safety and efficacy of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance, including unapproved compounds like MOTS-c.